Samsara Therapeutics
Oliver Kepp is Assistant Professor at University of Paris Descartes and Gustave Roussy Cancer Institute. Dr. Kep established the BioCELL screening platform, a state-of-the-art phenotypic screening facility and among the most sophisticated of its kind in Europe. Dr. Kepp has focused on systems biology approaches to immunogenic cell death, with expertise in automation and high throughput screening, automated bioimaging, and assay development for cell biological approaches. Previously, he was a Max Planck postdoctoral fellow at the Max Planck Institute for Infection Biology (Berlin, Germany); EMBO long term fellow at the INSERM research unit U848 at Gustave Roussy Cancer Center (Villejuif, France).
This person is not in any offices
Samsara Therapeutics
Samsara Therapeutics, Inc. is a biopharmaceutical company aiming to discover the first-in-class therapeutics that treat rare genetic and neurodegenerative diseases and extend a healthy lifespan. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy.